During the HIV era, a few reports of IRS emerged after the introduction of zidovudine monotherapy [4] [5] [6] . However, since the advent of HAART, many more publications have appeared describing patients with paradoxical reactions related to a variety of opportunistic infections [7] [8] [9] [10] [11] [12] [13] . A recent review identified 80 reported cases of nontuberculous mycobacterial IRS (NTM-IRS) [14] . The incidence, long-term outcome, and natural history of untreated NTM-IRS have not been previously defined. We report our experience with 51 patients with cases of NTM-IRS during the past decade. The initial findings for 11 of these cases were reported elsewhere [11] . 
PATIENTS AND METHODS
The study was conducted through the British Columbia Centre for Excellence in HIV/AIDS Drug Treatment Program, as described in detail elsewhere [15, 16] . Patients were identified by referral and were followed-up prospectively or by review of the British Columbia Centre for Excellence in HIV/AIDS Drug Treatment Program database. Cases were defined by the development of clinical disease (i.e., symptoms and/or physical signs) associated with all 3 of the following criteria: (1) samples from an inflammatory lesion or of normally sterile body fluid that were smear or culture positive for acid-fast bacilli, (2) a temporal association between the initiation of antiretroviral therapy and the onset of disease, and (3) evidence of a favorable response to antiretroviral therapy, arbitrarily defined as a reduction in HIV RNA load of at least 1 log 10 copies/mL or a 50% increase in CD4 + cell count, reaching a level of at least 50 cells/mL. Smear-positive but culture-negative cases were considered to be due to nontuberculous mycobacteria in the absence of a prior documented episode of Mycobacterium tuberculosis infection, because tuberculosis is rarely unmasked by antiretroviral-induced immune reconstitution [3, 14, 17] . Cases were further defined as definite if nontuberculous mycobacteria were demonstrated either in specimens of normally sterile tissue or in respiratory tract specimens in association with discrete endobronchial lesions. Cases in which nontuberculous mycobacteria were isolated from the respiratory tract in association with other pulmonary or thoracic lesions were defined as probable, provided that no other possible etiologies were documented. For patients with previous nontuberculous mycobacterial infection, clinical disease related to NTM-IRS was defined by the presence of new or worsening symptoms or physical signs. Nontuberculous mycobacterial infection was defined as disseminated if the organism was recovered from blood, bone marrow, or liver biopsy specimens; if the organism was only recovered from other sites, the infection was designated as localized infection. Adherence to HAART and MAC therapy was defined by the refill prescription rate, determined on the basis of pharmacy records [18] .
The incidence of NTM-IRS was determined by review of the provincial azithromycin prophylaxis program database [19] . In vitro susceptibility testing was performed for selected MAC isolates using the radiometric method (Bactec 12B [Becton Dickinson]; pH, 7.4) [20] . Isolates were considered to be susceptible if the MIC of clarithromycin was р8 mg/mL.
DATA ANALYSIS
Categorical variables were compared across the 4 different clinical presentation subgroups using contingency tables and x 2 tests of association. Fisher's exact test was used to calculate P values. Continuous variables were compared using the KruskalWallis nonparametric test. Where numerous comparisons were made, the significance level was adjusted using the Bonferroni correction to avoid a type I error. Of the patients included in the study, 84% were white and nonHispanic, 6% were aboriginal, 6% were Hispanic, 2% were black, and 2% were Asian. Risk factors for HIV infection included being a man who has sex with men (in 65% of the patients), injection drug use (25%), heterosexual sex (2%), being a man who has sex with men and injection drug use (2%), and having hemophilia (2%), and risk factors were unknown in 2% of cases. AIDS-defining diseases had been previously documented in 30 (59%) of the patients and were most often Pneumocystis jiroveci (formerly carinii) pneumonia (in 14 [27%]) and disseminated MAC infection (in 12 [24%]). Fortyone (80%) of the patients were referred to our clinical service and were followed-up prospectively; the other 10 (20%) were reviewed retrospectively. The median follow-up period was 29 months (interquartile range, 15-58 months). Between 1 June 1996 and 31 December 1997, the number of patients initiating or changing antiretroviral regimens with a baseline CD4 + cell count of !100 cells/mL who subsequently developed NTM-IRS was 13 (3.5%) of 368; the number of patients initiating or changing antiretroviral regimens with a baseline CD4 + cell count of !50 cells/mL who subsequently developed NTM-IRS was 8 (3.6%) of 220. The median interval from the initiation of HAART to the onset of symptoms (for the 48 cases for which such data was known) was 3 weeks (interquartile range, 1-8 weeks); the median interval from the initiation of HAART to the date of the diagnostic procedure for NTM-IRS was 10 weeks (interquartile range, 6-19 weeks). Antiretroviral regimens, both new (for 34 patients) and revised (for 17 patients), that were temporally associated with the development of NTM-IRS included 2 drugs (7 patients), 3 drugs (38 patients), 4 drugs (4 patients), 6 drugs (1 patient), and 9 drugs (1 patient). Ritonavir-boosted dual protease inhibitor combinations were only counted as a single antiretroviral.
RESULTS

Between
The presenting symptoms are listed in (8) , bronchoscopic examination (7), culture of specimens (6, including 3 of draining sinus specimens, 2 of sputum samples, and 1 of a blood specimen), laparotomy (3), and mediastinoscopic examination (1) . Mycobacterial smears of the relevant specimens were positive in 34 (68%) of 50 cases. One case (in patient 51) was diagnosed by blood culture, and mycobacterial smear was not i Seven of 8 sputum or BAL specimens and a supraclavicular node aspirate were all smear positive but culture negative for acid-fast bacilli; however, the patient had been receiving clarithromycin plus ethambutol for 7 months for MAC bacteremia (that was determined to be clarithromycin susceptible). Probes performed on a respiratory specimen for MAC RNA and Mycobacterium tuberculosis RNA were positive and negative, respectively. MAC therapy was discontinued at the time of NTM-IRS diagnosis. Fourteen months later, the patient developed NTM-IRS with abdominal lymphadenitis and abscess due to clarithromycin-resistant MAC, which responded to needle aspiration and 12 months of moxifloxacin plus ethambutol plus rifabutin. Tapering courses of prednisone for abdominal pain were as follows: patient 33 responded to 50 mg per day initially, experienced recurrent pain with a tapering dose, and received 22 months of prednisone in total; patients 34 responded to 50 mg per day, which was tapered and stopped after 5 weeks; patient 36 responded 3 times over a 6-month period to 50 mg per day, which was tapered and stopped each time after a few weeks; patient 40 responded twice to 50 mg per day, the dosage was tapered and stopped, and the patient experienced relapse; patient 41 had no response to prednisone 50 mg per day; patient 42 repeatedly responded to 4 courses of prednisone 50 mg per day initially but experienced relapse soon after stopping each time. Four culture-negative patients (patients 20, 27, 34, and 48) had cases that were presumed to be due to MAC on the basis of simultaneous or previous MAC bacteremia. In total, 44 (86%) of the cases were due to MAC, 2 (4%) were due to M. genavense, and 5 (10%) were due to unknown species. Antimycobacterial therapy was already being used at the time of NTM-IRS diagnosis in 21 (41%) of the patients, including primary MAC prophylaxis in 11 patients and secondary MAC prophylaxis in 10 patients. Among the 10 patients who developed NTM-IRS during combination antimycobacterial therapy, 8 were culture positive (7 for MAC and 1 for M. genavense), and 5 of 7 MAC isolates remained clarithromycin susceptible. Disease was usually localized. Cultures of blood samples (with or without bone marrow samples) showed no growth for 40 (91%) of 44 patients who underwent sampling at the time of NTM-IRS diagnosis; among the subset who were not receiving antimycobacterial therapy, blood cultures showed no growth for 21 (95%) of 22 patients.
Clinical characteristics are outlined according to the 4 patient groups in tables 3-6. Of cases of peripheral lymphadenopathy (table 3) , 7 were supraclavicular, 5 were cervical, 3 were inguinal, 1 was axillary, and 1 was preauricular. Among the pulmonary-thoracic disease group, 3 patients (patients 18, 27, and 30) also developed peripheral lymphadenopathy. Draining sinuses developed in 10 (59%) of 17 patients with peripheral lymphadenopathy but only in 1 (3%) of 34 other patients (patient 27). Sinus drainage continued for a median of 7 months (range, 1-19 months). Residual extensive scarring prompted plastic surgery in 2 patients, both of whom had a favorable result. Among the patients with pulmonary-thoracic disease, CT scan findings included mediastinal lymphadenopathy (10 patients, with hypodense centers in 4), parenchymal infiltrates (7), cavitary lesions (6), lung nodules (4), hilar lymphadenopathy (3), partial or complete lobar/segmental collapse (3), parenchymal tree-in-bud lesions (2), endobronchial nodules (2), and pericardial effusion (1). Acid-fast bacilli smears of 15 (28%) of 53 specimens obtained from 15 patients with pulmonarythoracic disease had positive results; specimens included 6 fineneedle aspirates, 6 bronchial biopsy specimens, 12 bronchoalveolar lavage specimens, and 29 sputum samples, of which 50%, 0%, 8%, and 38% were smear positive, respectively. Cultures positive for mycobacteria were obtained from 28 (60%) of 47 specimens submitted, including 6 fine-needle aspirates, 12 specimens of bronchoalveolar lavage fluid, and 29 sputum samples, of which 100%, 58%, and 52% had positive culture results, respectively. Bronchoscopic examinations were performed for 13 patients (12 of whom had pulmonary-thoracic disease, and 1 of whom had peripheral lymphadenopathy); in 5 (38%) of these patients, bronchoscopic examination revealed 1-6 endobronchial lesions (either nodular, polypoid, sessile, or necrotic). Partial or complete bronchial obstruction was demonstrated for 4 patients (intrinsic in 3 patients and extrinsic in 1 patient), 3 of whom also had documented endobronchial lesions.
All 13 patients with intra-abdominal disease had imaging that demonstrated intra-abdominal lymphadenopathy (hypodense centers in 7 patients). Intra-abdominal disease presentations also included peritonitis (4 patients), chylous ascites (2), duodenal lesions (2), intestinal obstruction (1), abscess (1), and an adrenal mass (1) . Comparison of the different groups showed that intra-abdominal disease was more often associated with prior nontuberculous mycobacterial infection, hospitalization, relapse, and lower CD4 + cell count ( (table 7) . Duration of symptoms could be determined for 39 (76%) of the patients; the median duration of symptoms was 6 months (range, 0-27 months), with ongoing symptoms at last follow-up in 5 patients. The time to resolution of symptoms following the initiation of new therapy for MAC infection could be determined for 21 episodes; the median time to resolution of symptoms was 6 months (range, 2 weeks to 21 months). However, among 10 patients who received р2 weeks of antimycobacterial therapy, the median duration of symptoms was 3 months (range, 0-23 months). Overall mortality was 20%; 3 patients were lost to follow-up after 23-52 months. Death related to MAC occurred in 2 (4%) of the patients; in both patients, death was related to MAC bacteremia and recurrent CD4 + lymphopenia (CD4 + cell count, !50 cells/ mL). 
DISCUSSION
HAART results in a marked reduction in levels of circulating HIV RNA within 1-2 weeks after initiation of therapy [21] . This reduction in HIV RNA load is associated with an early increase in memory CD4 + cell count [22] , followed by an increase in naive CD4
+ cell count at 4-6 weeks after therapy initiation, which continues to account for the major portion of the increase in CD4 + cell count over time. The antiretroviral therapy-induced thymic enlargement is considered to be responsible for the naive CD4 + cell response [23] . These quantitative changes are associated with enhanced in vitro proliferative responses to various pathogens, including MAC [24] . The restoration of delayed hypersensitivity responses and cytokine production may be responsible for the inflammatory lesions that have been described in the various IRSs [25] .
We have described the clinical presentations, laboratory findings, and outcomes for 51 patients with HIV-related NTM-IRS. Three major presentations, accounting for 88% of cases, were identified, including peripheral lymphadenitis, pulmonary-thoracic disease, and intra-abdominal disease. Although there is no widely accepted clinical definition of HIV-related IRS, we propose the definition outlined above (see Patients and Methods). The temporal association between IRS and initiation of HAART has occasionally not been straightforward, as in our 2 patients with musculoskeletal cases (patients 46 and 47), for whom the intervals between initiation of HAART and the onset of symptoms were ∼1 and ∼2 years, respectively. The late onset of IRS due to MAC has been described elsewhere in patients with bone involvement [26] . Occasionally, patients presenting with NTM-IRS have not yet had a significant increase in CD4 + cell count, despite having a virologic response (patients 5, 17, 22, 37, and 45). Conversely, other individuals whose CD4 + cell count increased may have had a discordant virologic response or, at the time of NTM-IRS diagnosis, may have already discontinued HAART and had a viral rebound. Consequently, we do not consider that both a CD4 + cell and virologic response are required to make the diagnosis, as has been suggested elsewhere [8] . Also, the diagnosis of HIV-related IRS does not depend on an AIDS diagnosis, given that some of the conditions (such as herpes zoster) are not AIDS-defining. HIV-related MAC infection prior to the era of HAART typically presented as disseminated disease with chronic, nonspecific symptoms, such as fever, night sweats, and weight loss, and was often associated with abdominal pain, diarrhea, and cytopenias [27] . Atypical clinical features of HIV-related nontuberculous mycobacterial infection provide important clues to the diagnosis of NTM-IRS and include the presence of localized disease [11, 12] , endobronchial lesions [4, 9] , massive lymphadenopathy, draining sinuses [11] , and atypical infection locations, such as skin or bone [5, 26] . Atypical features were usually present in this case series, but there were several exceptions (patients 1, 34, 42, and 51). Our patients were predominantly white men who have sex with men; however, the results may have differed for other populations. Sites of disease in this series included all of the major lymph node regions, the thorax, the abdomen, and various other sites of disease. Constitutional symptoms were the most common type of symptom; however, chief complaints related to almost every organ system. Disease severity ranged from asymptomatic lymphadenopathy to vertebral osteomyelitis with spinal cord compression. Approximately one-half of the patients required hospitalization, most often for abdominal or pulmonary-thoracic disease. The median interval from initiation of HAART to the onset of symptoms was 3 weeks; however, the median interval from the onset of symptoms to the date of a diagnostic procedure was 6 weeks. Diagnostic delays were often related to a lack of physician awareness of IRS. The most frequent provisional diagnoses were mycobacterial infection or lymphoma; however, IRS was usually not initially included in the differential diagnosis.
A number of differences were observed between the clinical groups. Fever was more frequent among patients with abdominal or pulmonary-thoracic disease, whereas draining sinuses only occurred in patients with peripheral lymphadenopathy. Patients with abdominal cases were more likely to have previous disseminated MAC infection, lower CD4 + cell counts, and positive blood culture results at the time of NTM-IRS diagnosis, and they had higher rates of both hospitalization and relapse. These observations for patients with abdominal cases may be related to a greater burden of MAC infection before initiation of HAART, in addition to inadequate recovery of cell-mediated immunity [28] .
Primary [19] or secondary MAC prophylaxis did not protect against the development of NTM-IRS and was being used by 21 (41%) of the patients at presentation. Although 12 (24%) of the patients initially received antituberculous therapy pending species identification, IRS due to M. tuberculosis is very seldom encountered in the absence of recently documented tuberculosis [3, 14, 17] . In contrast, 38 (75%) of our patients with NTM-IRS had no prior history of mycobacterial disease and appeared to represent an unmasking of subclinical disease. Therapy most often consisted of clarithromycin plus ethambutol but, in most cases, was not temporally associated with symptom resolution. Rifabutin was usually not added to the regimen because of its limited efficacy [29] and concerns regarding antiretroviral drug interactions and polypharmacy. Antimycobacterial therapy was offered to all patients; however, 10 either declined or did not tolerate the regimen. Complete responses in 17 (33%) of the patients appeared to be unrelated to antimycobacterial therapy. Patients who received р2 weeks of antimycobacterial therapy experienced neither a longer duration of symptoms nor a higher relapse rate, compared with those who received prolonged therapy. However, given the observational study design, conclusions cannot be drawn regarding the role of antimycobacterial therapy. Prednisone therapy was usually associated with a favorable symptomatic response; however, 5 of 8 responders experienced relapse when it was tapered or stopped. The chronicity of symptoms for patients with intra-abdominal cases before initiation of corticosteroid therapy suggests that the high relapse rate among such patients was related to the site of disease, rather than being due to the use of corticosteroids. HAART was not interrupted as a management strategy for any of the patients in this series; however, this has been associated with resolution of symptoms in a few Table 8 .
Clinical responses and outcome for 51 patients with nontuberculous mycobacterial immune reconstitution syndrome (NTM-IRS).
ther of which were associated with clinical or microbiologic responses in randomized trials involving MAC bacteremia [32, 33] .
Only 3.5% of our patients with CD4 + cell counts !100 cells/ mL developed NTM-IRS after the initiation of HAART. Shelburne et al. [34] observed the development of IRS in 11 (31%) of 35 patients with previously documented MAC infection who received HAART. However, the risk related to any of the various IRS syndromes may be as high as 25% among those patients with CD4
+ lymphopenia [35] , making it appropriate to counsel patients regarding the possibility of such an event in the same context as the discussion of adverse drug events.
In summary, we have determined the incidence of NTM-IRS and have identified 3 major clinical presentations. A number of distinct differences associated with the intra-abdominal cases have also been outlined, including higher morbidity. The absence of a convincing, temporally related clinical response to specific antimycobacterial therapy among most patients and the generally favorable outcome for those who received little or no antimycobacterial therapy raises questions regarding both the efficacy and necessity of specific treatment in many of these patients. In contrast to HIV-related tuberculosis, when problems develop regarding issues of polypharmacy in the management of NTM-IRS, the priority should be the HAART. The role of prednisone in selected patients is supported by the observation of prompt clinical responses and the recurrence of symptoms on tapering or withdrawal of therapy, particularly in patients with severe intra-abdominal disease. The long-term prognosis is generally favorable, particularly for those who remain adherent to HAART and have nonabdominal disease.
